Published in J Cardiovasc Pharmacol on January 01, 1987
Ageing, serotonin and ketanserin. Drugs (1988) 0.79
Ketanserin in the treatment of diabetes-associated hypertension. Drugs (1988) 0.75
Ketanserin, an effective third-line agent in primary hypertension. Drugs (1988) 0.75
Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin. Drugs (1988) 0.75
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med (1978) 5.04
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J (2003) 3.78
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med (1972) 3.73
Elevation of troponin I in sepsis and septic shock. Intensive Care Med (2001) 3.47
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens (1994) 2.91
A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet (1977) 2.90
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J (2004) 2.73
The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J (2002) 2.68
Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 2.61
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol (1987) 2.36
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med (1979) 2.31
One-year mortality among unselected outpatients with heart failure. Eur Heart J (2002) 2.30
Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation (1992) 2.15
Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med (1972) 2.10
Serum level monitoring of antibacterial drugs. A review. Clin Pharmacokinet (1985) 2.01
Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol (1975) 2.00
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet (1981) 1.99
Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation (1990) 1.98
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Improvement of chronic congestive heart-failure by oral captopril. Lancet (1979) 1.94
Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol (1998) 1.92
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol (1981) 1.88
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther (1981) 1.88
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens (2001) 1.87
Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med (1998) 1.83
Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol (2000) 1.82
An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med (1974) 1.82
Angiotensin II receptor antagonists. Lancet (2000) 1.82
Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension (1980) 1.81
Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens (2001) 1.80
Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet (1973) 1.78
Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) J Am Coll Cardiol (1990) 1.76
Nifedipine in hypertensive emergencies. Br Med J (Clin Res Ed) (1983) 1.75
Management of patients with heart failure in clinical practice: differences between men and women. Heart (2007) 1.73
Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther (1983) 1.73
Endothelial function in chronic congestive heart failure. Am J Cardiol (1992) 1.69
Decreased Beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension. Hypertension (1980) 1.69
A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J (1999) 1.66
Conduit artery compliance and distensibility are not necessarily reduced in hypertension. Hypertension (1992) 1.64
Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol (1997) 1.62
Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med (1986) 1.60
A stroke of luck in a 90-year-old. Lancet (2004) 1.58
A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary Artery. Mayo Clin Proc (2000) 1.58
Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol (1987) 1.56
Fatal pancytopenia associated with the use of captopril. Ann Intern Med (1981) 1.54
Dyspnea after pneumonectomy: the result of an atrial septal defect. Ann Thorac Surg (1997) 1.54
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol (1983) 1.54
Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation. Clin Pharmacol Ther (1982) 1.51
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet (1995) 1.51
Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension (1990) 1.47
Simple point-of-care risk stratification in acute coronary syndromes: the AMIS model. Heart (2008) 1.45
Changes of immunoregulatory cells induced by psychological and physical stress: relationship to plasma catecholamines. Clin Exp Immunol (1984) 1.45
The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest (1970) 1.42
A comparison of quality-of-life in patients with dual chamber pacemakers and individually programmed atrioventricular delays. Pacing Clin Electrophysiol (1996) 1.41
Importance of an individually programmed atrioventricular delay at rest and on work capacity in patients with dual chamber pacemakers. Pacing Clin Electrophysiol (1994) 1.41
Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients? Eur Respir J (2002) 1.41
The impact of statin treatment on presentation mode and early outcomes in acute coronary syndromes. Cardiology (2007) 1.40
Is blood pressure response to the Valsalva maneuver related to neurohormones, exercise capacity, and clinical findings in heart failure? Chest (1999) 1.40
Calcium channels in thrombin-activated human platelet membrane. Nature (1988) 1.39
[Cardiac interventions in Switzerland 1992. PTCA and Fibrinolysis Work Group of the Swiss Cardiology Association]. Schweiz Med Wochenschr (1994) 1.39
[Insulin--a side issue or indeed the cause of hypertension?]. Dtsch Med Wochenschr (1991) 1.39
Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res (1990) 1.37
Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol (1987) 1.37
Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. Am J Pathol (1992) 1.36
Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. N Engl J Med (1984) 1.34
Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant (1999) 1.32
Silicone stents in the management of inoperable tracheobronchial stenoses. Indications and limitations. Chest (1993) 1.32
Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells. Biochem Biophys Res Commun (1988) 1.32
Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation (1978) 1.30
Angiotensin II, vasopressin, and sympathetic activity in conscious rats with endotoxemia. Am J Physiol (1985) 1.29
Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res (1975) 1.27
Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone? Heart (1999) 1.26
Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension (1998) 1.25
Synergistic effects of fluid shear stress and cyclic circumferential stretch on vascular endothelial cell morphology and cytoskeleton. Arterioscler Thromb Vasc Biol (1995) 1.25
Exercise capacity as a predictor of postoperative complications in lung resection candidates. Am J Respir Crit Care Med (1995) 1.25
Phosphorylation of serine 2843 in ryanodine receptor-calcium release channel of skeletal muscle by cAMP-, cGMP- and CaM-dependent protein kinase. Biochim Biophys Acta (1993) 1.24
Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem (2000) 1.23
Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension (1990) 1.23
Induction of growth-related metabolism in human vascular smooth muscle cells by low density lipoprotein. J Biol Chem (1989) 1.23
Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure. Lancet (1978) 1.23
Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation (1998) 1.22
Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension. J Clin Invest (1972) 1.21
Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax (1991) 1.20
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther (1999) 1.20
Compliance with antihypertensive treatment: implications for practice. Blood Press (1997) 1.19
Endothelium-dependent responses in carotid and renal arteries of normotensive and hypertensive rats. Hypertension (1988) 1.19
Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline. Am Rev Respir Dis (1982) 1.18
Activation of phospholipase A2 by endothelin in cultured vascular smooth muscle cells. Biochem Biophys Res Commun (1989) 1.18
Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol (1995) 1.16
Proximal sodium reabsorption: An independent determinant of blood pressure response to salt. Hypertension (2000) 1.16
Hypertension of renal origin: evidence for two different mechanisms. Science (1971) 1.16